Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.

Molly Brewer,Roberto Angioli, Giovani Scambia,Domenica Lorusso,Corrado Terranova,Pierluigi Benedetti Panici,Francesco Raspagliesi,Paolo Scollo,Francessco Plotti,Gabriella Ferrandina,Vanda Salutari,Caterina Ricci,Patricia Braly,Robert Holloway,Michael Method,Madi Madiyalakan, Eliel Bayever,Christopher Nicodemus

Gynecologic Oncology（2020）

引用 33|浏览73

暂无评分

摘要

•Oregovamab is an antibody against CA125.•Oregovamab with chemotherapy for ovarian cancer improved progression free survival and overall survival.•Oregovamab did not result in any additional toxicity.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要